StockData
Alpha Teknova, Inc. logo

Alpha Teknova, Inc. (TKNO) stock

TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30124% above fair value
$7.65−0.12 (-1.54%)

Close on Nov 17, 2026Market cap $410.72MP/E –Yield –

Alpha Teknova operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Alpha Teknova's operating income for the twelve months ending Jun 30, 2026 was -$15.81M. For fiscal 2025 it was -$16.98M. The highest annual figure on record is $4.66M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$16.98M–
FY2024Dec 31, 2024-$26.15M–
FY2023Dec 31, 2023-$35.56M–
FY2022Dec 31, 2022-$49.66M–
FY2021Dec 31, 2021-$12.01M-357.5%
FY2020Dec 31, 2020$4.66M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.89M–
Q1 FY2026Mar 31, 2026-$4.30M–
Q4 FY2025Dec 31, 2025-$4.61M–
Q3 FY2025Sep 30, 2025-$4.02M–
Q2 FY2025Jun 30, 2025-$3.39M–
Q1 FY2025Mar 31, 2025-$4.96M–
Q4 FY2024Dec 31, 2024-$5.63M–
Q3 FY2024Sep 30, 2024-$7.43M–
Q2 FY2024Jun 30, 2024-$5.10M–
Q1 FY2024Mar 31, 2024-$7.99M–
Q4 FY2023Dec 31, 2023-$10.86M–
Q3 FY2023Sep 30, 2023-$8.76M–
Q2 FY2023Jun 30, 2023-$7.00M–
Q1 FY2023Mar 31, 2023-$8.95M–
Q4 FY2022Dec 31, 2022-$14.24M–
Q3 FY2022Sep 30, 2022-$22.95M–
Q2 FY2022Jun 30, 2022-$6.63M–
Q1 FY2022Mar 31, 2022-$5.84M–
Q4 FY2021Dec 31, 2021-$4.77M-699.6%
Q3 FY2021Sep 30, 2021-$3.89M-280.7%
Q2 FY2021Jun 30, 2021-$2.53M-458.8%
Q1 FY2021Mar 31, 2021-$828.00K–
Q4 FY2020Dec 31, 2020$795.00K–
Q3 FY2020Sep 30, 2020$2.15M–
Q2 FY2020Jun 30, 2020$704.00K–

More Alpha Teknova figures

See a number that looks wrong?